Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to […]
Building the team with experienced biotech experts and renowned leaders in the ADC field Underscores company’s commitment to progressing lead program on novel ADC target uPARAP Copenhagen, Denmark, December 1st, 2021 – Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announced today […]
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660) AMSTERDAM, NETHERLANDS, November 30, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the […]
Leucid Bio: Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods 4basebio PLC (AIM: 4BB), the specialist life sciences group focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines, is pleased to announce a Joint Development Agreement (“JDA”) between its wholly owned subsidiary 4basebio Discovery […]
Plans to recommence enrolment in the ACTIVATE clinical trial and new trial in pancreatic cancer in the US. OSLO/LONDON: 18 NOVEMBER, 2021: Exact Therapeutics AS (“EXACT-Tx”, or “the Company” Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces a number of strategic, operational and scientific […]
